Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 26 — CRO sector surges in bio revolution

Biotechnology
Simon Wentworth
24 October 2023
episode26-large-podcast

More on this story...

Pharmaceutical
Two new hires at Asia-Pacific-focused CRO Novotech
13 October 2023
Biotechnology
Singaporean CRO Novotech appoints new chief medical officer
4 October 2023
Pharmaceutical
Growing CDMO appoints new president of Novasep business
19 October 2023
Pharmaceutical
Data show outsourcing growth set to continue in future
1 December 2023


More ones to watch >


Today's issue

Nektar sells its PEGylation reagent manufacturing business
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024
Ascendis and Novo Nordisk sign deal on metabolic and CV diseases
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze